Compare AMAR REMEDIES with LINC PEN &PL - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs LINC PEN & PLASTICS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES LINC PEN & PLASTICS AMAR REMEDIES/
LINC PEN & PLASTICS
 
P/E (TTM) x -0.5 16.0 - View Chart
P/BV x 0.1 2.9 2.1% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 AMAR REMEDIES   LINC PEN & PLASTICS
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
LINC PEN & PLASTICS
Mar-16
AMAR REMEDIES/
LINC PEN & PLASTICS
5-Yr Chart
Click to enlarge
High Rs164243 67.6%   
Low Rs86136 63.2%   
Sales per share (Unadj.) Rs261.6232.7 112.4%  
Earnings per share (Unadj.) Rs17.412.4 140.4%  
Cash flow per share (Unadj.) Rs22.316.4 135.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs100.768.4 147.3%  
Shares outstanding (eoy) m26.1614.79 176.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.50.8 58.7%   
Avg P/E ratio x7.215.3 47.0%  
P/CF ratio (eoy) x5.611.5 48.6%  
Price / Book Value ratio x1.22.8 44.8%  
Dividend payout %024.2 0.0%   
Avg Mkt Cap Rs m3,2702,800 116.8%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m163186 87.8%   
Avg. sales/employee Rs ThNM5,167.3-  
Avg. wages/employee Rs ThNM278.8-  
Avg. net profit/employee Rs ThNM275.1-  
INCOME DATA
Net Sales Rs m6,8443,441 198.9%  
Other income Rs m217 284.6%   
Total revenues Rs m6,8653,449 199.1%   
Gross profit Rs m1,131314 360.3%  
Depreciation Rs m12860 214.6%   
Interest Rs m39815 2,601.3%   
Profit before tax Rs m626246 254.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m12163 191.5%   
Profit after tax Rs m455183 248.4%  
Gross profit margin %16.59.1 181.2%  
Effective tax rate %19.325.6 75.4%   
Net profit margin %6.65.3 124.9%  
BALANCE SHEET DATA
Current assets Rs m4,9041,334 367.7%   
Current liabilities Rs m3,581802 446.7%   
Net working cap to sales %19.315.5 125.0%  
Current ratio x1.41.7 82.3%  
Inventory Days Days12482 151.6%  
Debtors Days Days10051 197.9%  
Net fixed assets Rs m1,689437 386.2%   
Share capital Rs m262148 177.2%   
"Free" reserves Rs m2,358863 273.1%   
Net worth Rs m2,6351,011 260.6%   
Long term debt Rs m5070-   
Total assets Rs m6,8621,855 370.0%  
Interest coverage x2.617.1 15.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.01.9 53.8%   
Return on assets %12.410.7 116.2%  
Return on equity %17.318.1 95.3%  
Return on capital %31.025.9 119.8%  
Exports to sales %4.027.9 14.3%   
Imports to sales %016.0 0.0%   
Exports (fob) Rs m273959 28.5%   
Imports (cif) Rs mNA552 0.0%   
Fx inflow Rs m273960 28.4%   
Fx outflow Rs m2577 0.3%   
Net fx Rs m271383 70.7%   
CASH FLOW
From Operations Rs m-31397 -322.6%  
From Investments Rs m-489-185 264.5%  
From Financial Activity Rs m76974 1,037.5%  
Net Cashflow Rs m-33-14 236.5%  

Share Holding

Indian Promoters % 25.5 60.4 42.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 9.2 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 39.6 164.9%  
Shareholders   13,061 6,688 195.3%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   ARCHIES LTD  MARICO  K.S.OILS LTD  BAJAJ CONSUMER CARE  GILLETTE INDIA  

Compare AMAR REMEDIES With:   UNILEVER PLC. (UK)  P&G (US)  HYPERMARCAS (Brazil)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 5-YR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS